Potential opportunity in the development of new therapeutic agents based on endogenous and exogenous inhibitors of the proprotein convertases.
The proprotein convertases (PCs) are responsible for the endoproteolytic processing of various protein precursors (e.g., growth factors, receptors, adhesion molecules, and matrix metalloproteinases) implicated in several diseases such as obesity, diabetes, atherosclerosis, cancer, and Alzheimer disease. The potential clinical and pharmacological role of the PCs has fostered the development of various PC-inhibitors. In this review we summarized the recent findings on PCs inhibitors, their mode of actions and potential use in the therapy of various diseases.
Bontemps
Yannick
Y
INSERM, U 716, Equipe AVENIR, Institut de Génétique Moléculaire, Paris 75010, France.
Scamuffa
Nathalie
N
Calvo
Fabien
F
Khatib
Abdel-Majid
AM
D006801:Humans; D008954:Models, Biological; D008958:Models, Molecular; D043484:Proprotein Convertases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011480:Protease Inhibitors / Q000737:chemistry* / Q000627:therapeutic use*
D011480:Protease Inhibitors; D043484:Proprotein Convertases